Azithromycin and the risk of cardiovascular complications

Journal of Pharmacy Practice

Volumn 27, Issue 5, 2014, Pages 496-500

  Maisch, Nicole M ^a,b   Kochupurackal, Jenny G ^a   Sin, Jonathan ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

arrhythmia; azithromycin; cardiovascular death; QT prolongation; torsades de pointes

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CHLOROQUINE; CIPROFLOXACIN; LEVOFLOXACIN; PENICILLIN V; ANTIINFECTIVE AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DRUG FATALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART DEATH; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HIGH RISK POPULATION; HUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRESCRIPTION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TORSADE DES POINTES; AGE; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; MORTALITY; RISK FACTOR;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; AZITHROMYCIN; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; HUMANS; RISK FACTORS;

EID: 84908892771     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013516503     Document Type: Review

References (23)

1. Food and Drug Administration. FDA statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. http://www.fda.gov/Drugs/DrugSafety/ucm304372.htm. Accessed June 1, 2013.
2. Food and Drug Administration. Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm. Accessed June 1, 2013.
3. New York, NY: Pfizer Inc ; Feb 2013:
4. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012 ; 366 (20). 1881-1890
5. Van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010 ; 70 (1). 16-23
6. Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006 ; 43 (12). 1603-1611
7. International Conference on Harmonization. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.http://www.fda.gov/RegulatoryInformation/Guidances/ucm129335.htm. Accessed June 1, 2013.
8. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013 ; 368 (18). 1704-1712
9. Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval?. Wien Klin Wochenschr. 2002 ; 114 (10-11). 396-399
10. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 ; 365 (8). 689-698
11. Poluzzi E, Raschi E, Moretti U, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA adverse event reporting system (AERS). Pharmacoepidemiol Drug Saf. 2009 ; 18 (6). 512-518
12. Samarendra P, Kumari S, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol. 2001 ; 24 (10). 1572-1574
13. Matsunaga N, Oki Y, Prigollini A. A case of QT prolongation precipitated by azithromycin. N Z Med J. 2003 ; 116 (1185). U666
14. Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol. 2005 ; 28 (11). 1221-1222
15. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed. 2006 ; 77 (1). 30-32
16. Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol. 2007 ; 18 (3). 243-246
17. Huang B, Wu C, Hsia C, et al. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol. 2007 ; 30 (12). 1579-1582
18. Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. Mo Med. 2010 ; 107 (1). 53-58
19. Santos N, Oliveira M, Galrinho A, et al. QT interval prolongation and extreme bradycardia after a single dose of azithromycin. Rev Port Cardiol. 2010 ; 29 (1). 139-142
20. Winton JC, Twilla JD. Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. Am J Med Sci. 2013 ; 345 (2). 160-162
21. Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med. 2013 ; 368 (18). 1665-1668
22. Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010 ; 65 (9). 631-640
23. Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf. 2010 ; 5 (1). 85-92